CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

meplazumab for injectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1557 favipiravir tablets+chloroquine phosphatetablets tablets Wiki 1.00
drug513 Favipiravir tablets Wiki 1.00
drug1016 Placebo Wiki 0.08

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.07
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 A Single Center, Double-blinded, ,Placebo-controlled Phase I Clinical Trial in Healthy Volunteer to Evaluate Tolerance and Pharmacokinetics of Meplazumab of Injection

This is a single center, double-blinded, placebo-controlled phase I clinical trail in healthy volunteer of meplazumab for injection. The primary objective of this phase I trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and occupancy characteristics of peripheral blood cell receptors of meplazumab in healthy volunteer, and provide a reference for the dosage of meplazumab in phase II clinical trial.

NCT04369586 Healthy Volunteers Drug: meplazumab for injection Drug: Placebo

Primary Outcomes

Description: Nature, incidence, and severity of AEs/SAEs, and the relationship to meplazumab treatment.

Measure: Incidence rate of treatment-related adverse events as assessed by CTCAE v5.0

Time: 0-28 days

Secondary Outcomes

Description: AUC0-tn

Measure: Pharmacokinetic assessments of meplazumab- AUC0-tn

Time: 0-28 days

Description: AUC0-∞

Measure: Pharmacokinetic assessments of meplazumab- AUC0-∞

Time: 0-28 days

Measure: Pharmacokinetic assessments of meplazumab-half life time

Time: 0-28 days

Description: Maximum observed plasma concentration of meplazumab (Cmax)

Measure: Pharmacokinetic assessments of meplazumab-Cmax

Time: 0-28 days

No related HPO nodes (Using clinical trials)